Heparin-bonded circuits improve clinical outcomes in emergency coronary artery bypass grafting

Journal of Cardiac Surgery

Volumn 12, Issue 6, 1997, Pages 389-397

  Aldea, Gabriel S ^a,b   Lilly, Kevin ^a   Gaudiani, Jennifer M ^a   O'Gara, Paul ^a   Stein, Darryl ^a   Bao, Yusheng ^a   Treanor, Patrick ^a   Osman, Ashraff ^a   Shapira, Oz M ^a   Lazar, Harold L ^a   Shemin, Richard J ^a  

^a BOSTON MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; EMERGENCY SURGERY; FEMALE; HEPARINIZATION; HOSPITALIZATION; HUMAN; INOTROPISM; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; POSTOPERATIVE COMPLICATION;

EID: 7344226184     PISSN: 08860440     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8191.1997.tb00157.x     Document Type: Article

References (29)

1. Borkon AM, Failing TL, Piehler JM, et al: Risk analysis of operative intervention for failed coronary angioplasty. Ann Thorac Surg 1992;54:884-891.
2. Grover FL (ed): Data Analyses of the Society of Thoracic Surgeons National Cardiac Surgery Database. January 1997;136-139.
3. Lazar HL, Haan CK. Determinants of myocardial infarction following emergency coronary artery bypass for failed percutaneous coronary angioplasty. Ann Thorac Surg 1987;44:646-650.
4. Greaves SC, Rutherford JD, Aranki SF, et al: Current incidence and determinants of perioperative myocardial infarction in coronary artery surgery. Am Heart J 1996;132:572-578.
5. Fosse E, Oddvar M, Johnson E, et al: Reduced complement and granulocyte activation with heparin coated cardiopulmonary bypass. Ann Thorac Surg 1994;58:472-477.
6. Wendel HP, Heller W, Hoffmeister HE. Pathway of platelet protection in heparin-coated devices and its significance for cardiac surgery. Trans Soc Biomatter 1995;21:281.
7. Gu YJ, van Oeveren W, Akkerman C, et al: Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993;55:917-922.
8. Pekna M, Hagman L, Halden E, et al: Complement activation during cardiopulmonary bypass: Effects of immobilized heparin. Ann Thorac Surg 1994;58:421-424.
9. Gorman RC, Ziats NP, Gikakis N, et al: Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996;111:1-12.
10. Ovrum E, Mollnes TE, Fosse E, et al: High and low heparin dose with heparin-coated cardiopulmonary bypass circuits: Activation of complement and granulocytes. Ann Thorac Surg 1995 ;60:1755-1761.
11. Jansen PGM, Velthuis H, Huybregts RAJM, et al: Reduced complement activation and improved post-operative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg 1995; 110:829-834.
12. Edmunds LH Jr. Surface-bound heparinpanacea or peril? Ann Thorac Surg 1994;58:285-286.
13. Edmunds LH Jr. Breaking the blood-biomaterial barrier. ASAIO Journal 1995;41:824-830.
14. Gu YJ, van Oeveren W, van der Kamp KWHJ, et al: Heparin-coating of extracorporeal circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass. Perfusion 1991;6:221-225.
15. von Segesser LK, Weiss BK, Pasic M, et al: Risk and benefits of low systemic heparinization during open heart operations. Ann Thorac Surg 1994;58:391-398.
16. Ovrum E, Holen EA, Tangen G, et al: Completely heparinized cardiopulmonary bypass and reduced systemic heparin: Clinical and hemostatic effects. Ann Thorac Surg 1995;60:365-371.
17. Aldea GS, Doursounian M, O'Gara P, et al: Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: A prospective, randomized study. Ann Thorac Surg 1996; 62:410-418.
18. Aldea GS, Shapira OM, Osman A, et al: Effect of anticoagulation protocol on clinical outcomes in patients undergoing CABG with heparin-bonded circuits. Ann Thorac Surg 1998;65:425-435.
19. Fremes SE, Wong BI, Lee E, et al: Metaanalysis of prophylactic drug treatment in the prevention of post-operative bleeding. Ann Thorac Surg 1994;58:1580-1588.
20. Khuri SF, Valeri R, Losclazo J, et al: Heparin causes platelet dysfunction and indices of fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995;60:1008-1014.
21. Young JA, Kisher CT, Doty DB: Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and appearance of fibrin monomer. Ann Thorac Surg 1978;26: 231-240.
22. Cardoso PFG, Yamazaki F, Keshavjee S, et al: A reevaluation of heparin requirement during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;101:153-160.
23. Edwards FH, Grover FL, Shoyer AL, et al: The Society of Thoracic Surgeons National Cardiac Database: Current risk assessment. Ann Thorac Surg 1997;63:903-908.
24. Clark RE: Calculating risk and outcome: The Society of Thoracic Surgeons Database. Ann Thorac Surg 1996;62(Suppl)S2-S5.
25. Brandrup-Wognsen D, Haglid M, Karlsson T, et al: Mortality during two years after coronary artery bypass grafting in relation to peri-operative factors and urgency of operation. Eur J Cardiothorac Surg 1995;9:685-691.
26. Simel D, Samsa G, Matchar D: Likelihood ratios for continuous test resultsmaking the clinicians' job easier or harder? J Clin Epidemiol 1993; 46:85-93.
27. Lagakos SW: Effects of mismodeling and mismeasuring explanatory variables on tests of association with a response variable. Stat Med 1988;7:257-274.
28. Cohen J, Cohen P: Applied Multiple Regression/correlation Analysis for Behavioral Sciences, Second Edition. Hillsdale, New Jersey, Lawrence Erlbaum Associates, Inc., 1983.
29. Alderman EL, Andrews K, Bost J, et a:. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. New Engl J Med 1996;335:217-225.